References
Barbui C, Tansella M, Garattini S (2003) Varying and "atypical" indications for atypical antipsychotics. Psychopharmacology DOI 10.1007/s00213-003-1495-x
Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371–1376
Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, Lieberman JA, Lopez-Ibor JJ, van Raay B, Twomey E (2002) The usefulness and use of second-generation antipsychotic medications. Curr Opin Psychiatry 15[Suppl 1]:S1–S51
Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, Lieberman JA, Lopez-Ibor JJ, van Raay B, Twomey E (2003) The usefulness and use of second-generation antipsychotic medications—an update. Curr Opin Psychiatry 16[Suppl 1]:S1–S44
Weiss E, Hummer M, Koller D, Ulmer H, Fleischhacker WW (2000) Off-label use of antipsychotic drugs. J Clin Psychopharmacol 20:695–698
Acknowledgements
The European Group for Research in Schizophrenia comprises: Istvan Bitter, Tom Burns, Michael Davidson, W. Wolfgang Fleischhacker, Silvana Galderisi, Jes Gerlach, Rene Kahn, Jan Libiger, Juan Jose Lopez-Ibor, Dieter Naber, Manuel Paes de Sousa, Joseph Peuskens, Wulf Rössler and Goran Sedvall.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Fleischhacker, W.W., the European Group for Research in Schizophrenia. Second-generation antipsychotics: discrepancies between licensed indications, evidence base and actual use. Psychopharmacology 169, 207–210 (2003). https://doi.org/10.1007/s00213-003-1496-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-003-1496-9